GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » TearLab Corp (OTCPK:TEAR) » Definitions » Quick Ratio

TearLab (TearLab) Quick Ratio : 0.24 (As of Mar. 2020)


View and export this data going back to 2004. Start your Free Trial

What is TearLab Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. TearLab's quick ratio for the quarter that ended in Mar. 2020 was 0.24.

TearLab has a quick ratio of 0.24. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for TearLab's Quick Ratio or its related term are showing as below:

TEAR's Quick Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.9
* Ranked among companies with meaningful Quick Ratio only.

TearLab Quick Ratio Historical Data

The historical data trend for TearLab's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TearLab Quick Ratio Chart

TearLab Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.36 3.22 2.06 3.39 0.24

TearLab Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.53 0.36 0.24 0.24

Competitive Comparison of TearLab's Quick Ratio

For the Diagnostics & Research subindustry, TearLab's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TearLab's Quick Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, TearLab's Quick Ratio distribution charts can be found below:

* The bar in red indicates where TearLab's Quick Ratio falls into.



TearLab Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

TearLab's Quick Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Quick Ratio (A: Dec. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(11.856-2.269)/39.755
=0.24

TearLab's Quick Ratio for the quarter that ended in Mar. 2020 is calculated as

Quick Ratio (Q: Mar. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(11.668-1.948)/41.124
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TearLab  (OTCPK:TEAR) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


TearLab Quick Ratio Related Terms

Thank you for viewing the detailed overview of TearLab's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TearLab (TearLab) Business Description

Traded in Other Exchanges
N/A
Address
150 LaTerraza Boulevard, Suite 101, Escondido, CA, USA, 92025
TearLab Corp is a part of the diagnostic industry. It is an in-vitro diagnostic company based in the United States. TearLab has commercialized a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The company operates through its wholly-owned subsidiary, TearLab Research Inc. Most of the company's revenue is derived from the United States region.
Executives
Anthony E Altig director C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, JERSEY CITY NJ 07302
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Lindstrom Richard L Md director 2811 WESTWOOD PL, WAYZATA MN 55391
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Adrienne L Graves director 125 STONE MOUNTAIN CIRCLE, NAPA CA 94558
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John Y Caloz officer: Chief Financial Officer ETON AVE, C/O INTERNATIONAL REMOTE IMAGING SYS, CHATSWORTH CA 91311